REDWOOD SHORES, Calif., April 8, 2008 Navigenics, agenetic health services company, today announced a new study of geneticpredisposition analysis. The Mayo Clinic study will examine how patientsunderstand and use information provided by a Navigenics genetic riskassessment. The research also addresses physicians' understanding of geneticassessments and the impact of such information on preventive health decisionmaking. Titled "A Proof of Principle Trial of Communication to PatientsReceiving Predictive Genetic Risk Assessment," the study begins this month andruns through September 2009. The study is funded jointly by Navigenics andMayo Clinic.
"In this emerging field it is absolutely critical that the entire industryremain rooted in high-quality science and research - this is exactly what wedo and what our customers, collaborators and advisors expect from Navigenics,"said Mari Baker, president and CEO of Navigenics. "We believe this researchcollaboration with a leading medical institution like Mayo Clinic will helpthe entire industry evolve responsibly, provide the necessary tools to educateclinicians, and ultimately improve people's lives."
The Navigenics(TM) Health Compass is a new genetic risk assessment servicethat combines an advanced genome scan with the latest discoveries in geneticmedicine and personalized genetic counseling. It gives individuals informationon their genetic predisposition to developing a broad menu of commonconditions, so that, with their physicians, they can seek earlier diagnosis,delay the onset or prevent the conditions altogether. The service calculatesgenetic predisposition based on genome-wide association studies that combine avariety of epidemiological variables. Navigenics scours the more than 4,000published studies correlating genes to medical conditions and other commonhuman traits to include only those which present high-quality and reliableresults. The Navigenics Health Compass is the only personal genetic riskassessment to provide on-staff Certified Genetic Counselors to help peopleunderstand their individual results.
"The science that links genes with many common inherited diseases is well-established and growing," said Navigenics co-founder and clinical advisoryboard chair David Agus, M.D. "Now we need to better understand how individualsuse this information. Navigenics hopes to learn more about patients' hopes andexpectations regarding genetic risk assessment. Our goal is to leverage thewealth of information that genetics can provide to better motivate patients totake action that will improve their health. Our research collaboration withthe Mayo Clinic helps us get there."
Navigenics, Inc. is a privately held company based in Redwood Shores,Calif. The company was founded by David Agus, M.D. and Dietrich Stephan,Ph.D., with the goal of improving health outcomes in individuals across thepopulation. Navigenics educates and empowers customers with knowledge of theirgenetic predispositions, and then motivates them to act on the information toprevent the onset of disease, achieve earlier diagnosis, appropriately managedisease, or otherwise lessen its impact. Navigenics' lead investors areKleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr DavidowVentures. More information is available at www.navigenics.com.FOR MORE INFORMATION: Hal Mackins Feinstein Kean Healthcare Hal.email@example.com (415) 677-2747 (415) 994-0040 - mobile Brenna Sweeney Navigenics firstname.lastname@example.org (206) 999-4796
SOURCE Navigenics, Inc.